Europe Cerebrospinal Fluid Management Market Growth and Recent Trends by 2028

The Europe cerebrospinal fluid management market is expected to reach US$ 988.78 million by 2028 from US$ 694.04 million in 2021; it is estimated to grow at a CAGR of 5.2% from 2021 to 2028.

The growth of the market is attributed to rising technological developments for CSF shunts and growing developments for CSF management products. However, the risk associated with CSF shunts hinders the market growth.

The never-ending technological developments are the unstoppable trend for the growth of CSF management market. The risk of diagnosing and treatment failure, limited control options, and complications have offered various opportunities for the product developers. Rising advancements in technology have introduced the concept of “smart shunt” that could offer hi-tech control, diagnosis, and communication-based shunts or implants. It is anticipated that designed smart shunts can control CSF drainage based on feedback from one or more measured conditions. Additionally, researchers expect that smart shunts have the potential to offer sophisticated control over mechanical shunts—data with respect to shunt malfunction. It is further expected to reduce the risk of shunt obstructions and eventually reduce the risk of failures.

Late-stage development companies operating in the market are demanding experimental results to seek approvals and commercialize the smart shunts. The primary focus is on shunts designed to assess ICP noninvasively in the physician’s office through an implanted pressure sensor and noninvasive assessment of CSF flow in the clinical settings. These on-demand sensing systems will be a significantly advanced supplement to existing mechanical valves.

The growing demand for better treatments has resulted in various product developments, resulting in the Europe cerebrospinal fluid management market growth. For instance, in July 2018, FDA granted breakthrough device designation to F. Hoffmann-La Roche Ltd for its Elecsys ß-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF. The products are used as in-vitro diagnostic immunoassays to measure ß-Amyloid (1-42) and Phospho-Tau concentrations in CSF among adults with cognitive impairment. They are evaluated for Alzheimer’s disease (AD) and other causes of dementia.

The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Spain, Italy, Germany, France, and the UK are among the most-affected European countries. The COVID-19 emergency has undoubtedly aided in encouraging the general population to try out and expand their usage of digital services, particularly to avoid visiting a health center in person. However, there are still a number of constraints that hinder these services from becoming widely adopted.

Inconsistent and interrupted supply chain activities and unavailability of human resources negatively impacted the cerebrospinal fluid management market growth. The sudden onset of pandemic led to shutdown of neurological wards and clinics across numerous countries. At the same time, hospitals ran out of resources owing to a huge number of COVID-19 patients. Consequently, according to one study, many diagnostic and treatment procedures had been cancelled or postponed around the world.

Europe  Cerebrospinal Fluid Management Market Revenue and Forecast to 2028 (US$ Mn)

EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET SEGMENTATION

By Product

• CSF shunts
• CSF drainage systems

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Neurological Centers

By Country

• U.K.
• Germany
• France
• Italy
• Spain
• Rest of Europe

Company Profiles

• Medtronic
• Integra Life Sciences Corporation
• B. Braun Melsungen AG
• DePuy Synthes
• Sophysa
• Dispomedica GmbH
• Möller Medical GmbH
• Natus Medical Incorporated
• Spiegelberg GmbH & Co. KG

Europe Cerebrospinal Fluid Management Report Scope